Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive Impairment

Objective:To observe the improvement of cognitive function and the changes of serum nerve influencing factors and cytokines in patients with stroke treated with repetitive transcranial magnetic stimulation (rTMS).Methods:A total of 100 patients with post-stroke congitive impairment (PSCI) were rando...

Full description

Saved in:
Bibliographic Details
Main Authors: Zheyi YU, Weiming ZHANG
Format: Article
Language:English
Published: Editorial Office of Rehabilitation Medicine 2019-10-01
Series:康复学报
Subjects:
Online Access:http://kfxb.publish.founderss.cn/thesisDetails#10.3724/SP.J.1329.2019.05020
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841537029831131136
author Zheyi YU
Weiming ZHANG
author_facet Zheyi YU
Weiming ZHANG
author_sort Zheyi YU
collection DOAJ
description Objective:To observe the improvement of cognitive function and the changes of serum nerve influencing factors and cytokines in patients with stroke treated with repetitive transcranial magnetic stimulation (rTMS).Methods:A total of 100 patients with post-stroke congitive impairment (PSCI) were randomly divided into observation group (<italic>n</italic>=51) and control group (<italic>n</italic>=49) by SAS software. The control group received routine treatment. On the basis of routine treatment, the observation group was treated with rTMS once a day, five times a week for eight weeks. Before and after treatment, the cognitive function scores of the two groups were compared, the changes of mini-mental state examination (MMSE) and Montreal cognitive function (MoCA) scores were compared, the activities of daily living (ADL) and auditory verbal learning test (AVLT) were observed. ELISA method was used to observe the changes of brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), interleukin-6(IL-6) and high-sensitivity C-reactive protein (hs-CRP) in the two groups after treatment.Results:There were no significant differences in the scores of MoCA, including orientation (ORT), visual space and executive function (EF), naming (NAM), memory (MEM), attention (ATT), language (LANG) and abstract ability (ABS) before treatment between the two groups (<italic>P</italic>&gt; 0.05). After eight weeks of treatment, ORT, EF, NAM, MEM, ATT, LANG and ABS in the two groups were significantly higher than those before treatment (<italic>P</italic>&lt; 0.05, <italic>P</italic>&lt; 0.01). The MoCA score of the observation group was significantly better than that of the control group (<italic>P</italic>&lt; 0.05). There were no significant differences in MMSE, AVLT123, AVLT5, AVLT recognition, ADL scores between the two groups before treatment (<italic>P</italic>&gt; 0.05). After treatment, the MMSE, AVLT123, AVLT5, AVLT recognition and ADL scores of the control group were (21.34±2.35), (9.15±3.36), (2.16±0.32), (15.24±2.62), (68.16±12.35), and those of the observation group were (25.21±3.45), (13.23±3.35), (2.24±1.62), (17.32±6.26), (74.43±15.34), the differences between the two groups were significantly higher than those before treatment (<italic>P</italic>&lt; 0.05, <italic>P</italic>&lt; 0.01), and the improvement of the observation group was better than that of the control group after treatment (<italic>P</italic>&lt; 0.05). There were no significant differences in serum BDNF, VEGF, IL-6 and hs-CRP levels before treatment between the two groups (<italic>P</italic>&gt; 0.05). After treatment, the serum levels of BDNF, VEGF, IL-6 and hs-CRP in the control group were (6.19±0.75) ng/mL, (113.25±11.35) pg/mL, (9.12±4.23) mmol/L, (3.74±1.47) mmol/L, and the serum levels of BDNF, VEGF, IL-6 and hs-CRP in the observation group were (8.25±0.94) ng/mL, (172.36±18.35) pg/mL, (6.78±3.86) mmol/L, (2.25±1.25) mmol/L, the serum levels of BDNF, VEGF, IL-6 and hs-CRP in the two groups were better than those before treatment (<italic>P</italic>&lt; 0.05, <italic>P</italic>&lt; 0.01), and the improvement in the observation group was significantly higher than that in the control group (<italic>P</italic>&lt; 0.05).Conclusion:rTMS can furtherly improve PSCI by improving cognitive function.
format Article
id doaj-art-64bf6636fbd64e11b8116eef14446068
institution Kabale University
issn 2096-0328
language English
publishDate 2019-10-01
publisher Editorial Office of Rehabilitation Medicine
record_format Article
series 康复学报
spelling doaj-art-64bf6636fbd64e11b8116eef144460682025-01-14T10:04:18ZengEditorial Office of Rehabilitation Medicine康复学报2096-03282019-10-0129202623130337Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive ImpairmentZheyi YUWeiming ZHANGObjective:To observe the improvement of cognitive function and the changes of serum nerve influencing factors and cytokines in patients with stroke treated with repetitive transcranial magnetic stimulation (rTMS).Methods:A total of 100 patients with post-stroke congitive impairment (PSCI) were randomly divided into observation group (<italic>n</italic>=51) and control group (<italic>n</italic>=49) by SAS software. The control group received routine treatment. On the basis of routine treatment, the observation group was treated with rTMS once a day, five times a week for eight weeks. Before and after treatment, the cognitive function scores of the two groups were compared, the changes of mini-mental state examination (MMSE) and Montreal cognitive function (MoCA) scores were compared, the activities of daily living (ADL) and auditory verbal learning test (AVLT) were observed. ELISA method was used to observe the changes of brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), interleukin-6(IL-6) and high-sensitivity C-reactive protein (hs-CRP) in the two groups after treatment.Results:There were no significant differences in the scores of MoCA, including orientation (ORT), visual space and executive function (EF), naming (NAM), memory (MEM), attention (ATT), language (LANG) and abstract ability (ABS) before treatment between the two groups (<italic>P</italic>&gt; 0.05). After eight weeks of treatment, ORT, EF, NAM, MEM, ATT, LANG and ABS in the two groups were significantly higher than those before treatment (<italic>P</italic>&lt; 0.05, <italic>P</italic>&lt; 0.01). The MoCA score of the observation group was significantly better than that of the control group (<italic>P</italic>&lt; 0.05). There were no significant differences in MMSE, AVLT123, AVLT5, AVLT recognition, ADL scores between the two groups before treatment (<italic>P</italic>&gt; 0.05). After treatment, the MMSE, AVLT123, AVLT5, AVLT recognition and ADL scores of the control group were (21.34±2.35), (9.15±3.36), (2.16±0.32), (15.24±2.62), (68.16±12.35), and those of the observation group were (25.21±3.45), (13.23±3.35), (2.24±1.62), (17.32±6.26), (74.43±15.34), the differences between the two groups were significantly higher than those before treatment (<italic>P</italic>&lt; 0.05, <italic>P</italic>&lt; 0.01), and the improvement of the observation group was better than that of the control group after treatment (<italic>P</italic>&lt; 0.05). There were no significant differences in serum BDNF, VEGF, IL-6 and hs-CRP levels before treatment between the two groups (<italic>P</italic>&gt; 0.05). After treatment, the serum levels of BDNF, VEGF, IL-6 and hs-CRP in the control group were (6.19±0.75) ng/mL, (113.25±11.35) pg/mL, (9.12±4.23) mmol/L, (3.74±1.47) mmol/L, and the serum levels of BDNF, VEGF, IL-6 and hs-CRP in the observation group were (8.25±0.94) ng/mL, (172.36±18.35) pg/mL, (6.78±3.86) mmol/L, (2.25±1.25) mmol/L, the serum levels of BDNF, VEGF, IL-6 and hs-CRP in the two groups were better than those before treatment (<italic>P</italic>&lt; 0.05, <italic>P</italic>&lt; 0.01), and the improvement in the observation group was significantly higher than that in the control group (<italic>P</italic>&lt; 0.05).Conclusion:rTMS can furtherly improve PSCI by improving cognitive function.http://kfxb.publish.founderss.cn/thesisDetails#10.3724/SP.J.1329.2019.05020strokecognitive impairmentrepetitive transcranial magnetic stimulationneurotrophic factorcell factor
spellingShingle Zheyi YU
Weiming ZHANG
Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive Impairment
康复学报
stroke
cognitive impairment
repetitive transcranial magnetic stimulation
neurotrophic factor
cell factor
title Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive Impairment
title_full Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive Impairment
title_fullStr Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive Impairment
title_full_unstemmed Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive Impairment
title_short Effect of Repetitive Transcranial Magnetic Stimulation on Patients with Post-Stroke Cognitive Impairment
title_sort effect of repetitive transcranial magnetic stimulation on patients with post stroke cognitive impairment
topic stroke
cognitive impairment
repetitive transcranial magnetic stimulation
neurotrophic factor
cell factor
url http://kfxb.publish.founderss.cn/thesisDetails#10.3724/SP.J.1329.2019.05020
work_keys_str_mv AT zheyiyu effectofrepetitivetranscranialmagneticstimulationonpatientswithpoststrokecognitiveimpairment
AT weimingzhang effectofrepetitivetranscranialmagneticstimulationonpatientswithpoststrokecognitiveimpairment